SEGOVA
Boosting Spectrum

In order to support and enhance the effects of SEGOVA ovarian rejuvenation, Professor Ljubić's team has introduced new technologies. The fundamental principle of Booster therapy involves the application of AMSC (fresh or thawed), which provides synergy and enhances the effects of individual types of stem cells.​

1. Apheresis Mobilized Stem Cells (AMSC):
AMSC are stem cells (mostly hematopoietic) from peripheral blood after bone marrow mobilization, collected via apheresis, a procedure involving blood collection from the venous system and isolation of stem cells using closed automated systems. The capacity of AMSC for differentiation, immunomodulation, and angiogenesis results in improvements in hormone levels, follicle activation, angiogenesis, and functional ovarian restoration. AMSC have anti-inflammatory and antioxidant properties that can reduce inflammation and oxidative stress in the ovaries and endometrium. Improving the ovarian microenvironment stimulates the improved quality of egg cells and reduces the risk of genetic abnormalities in offspring. This therapy is supported by growth factors hc PRP and bioregenerative fibrin BRF. There are two main differences compared to the standard SEGOVA program.

• Obtaining cells is much less complicated and not tied to invasive surgical procedures requiring hospitalization.

• The number of obtained cells is multiple times higher, as is the amount of material - allowing for freezing (cryopreservation) of the part that cannot be injected into the ovaries in one act and its storage for later intraovarian booster injections.

 
2. Cryopreserved Apheresis Mobilized Stem Cells (cAMSC):After thawing, they retain vitality and the positive effects of AMSC on ovarian tissue into which they are transplanted. This procedure is most commonly performed as a day procedure.
 
3. Therapeutic Plasma Exchange (TPE). Therapeutic plasma exchange refreshes the patient's plasma by removing particles contributing to functional disruption and aging. TPE involves the removal, treatment, and return of blood plasma to the body, promoting a transition to a younger systemic proteome, including pro-regenerative, anti-cancer, and apoptotic regulators in circulating cells. These cells have reduced cellular senescence and less DNA damage.